Last update Aug. 22, 2019

Eletriptan Hydrobromide


Safe substance and/or breastfeeding is the best option.

Selective agonist for the vascular receptor of 5-hydroxytryptamine-1 (5-HT1, serotonin) with vasoconstrictor action at the intracranial level.
Indicated in acute migraine attack.
Oral administration in a daily dose.

It is excreted in breastmilk in clinically insignificant amounts: 0.02% of the maternal dose (AEMPS-Pfizer 2013).

Its low oral bioavailability impedes its transfer from breastmilk into infant plasma, except in premature infants and the immediate neonatal period when there may be greater intestinal permeability.

Several expert authors consider its use to be safe or probably safe during breastfeeding (Hale 2019, Briggs 2017, Amundsen 2015, Davanzo 2014, Hutchinson 2013, Duong 2010).

Its use, usually in isolated doses, makes the occurrence of adverse effects in infants unlikely (Jürgens 2009).


  • Sumatriptan (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Eletriptan Hydrobromide in other languages or writings:


Eletriptan Hydrobromide belongs to this group or family:


Main tradenames from several countries containing Eletriptan Hydrobromide in its composition:


Variable Value Unit
Oral Bioavail. 50 %
Molecular weight 463 daltons
Protein Binding 85 %
VD 2 l/Kg
pKa 16.56 -
Tmax 1.5 - 2 hours
4 - 5 hours
M/P ratio 0.25 -
Relative Dose 0.02 %


  1. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from Consulted on April 10, 2024 Full text (link to original source)
  2. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. Tenth edition (acces on line) 2015
  3. Amundsen S, Nordeng H, Nezvalová-Henriksen K, Stovner LJ, Spigset O. Pharmacological treatment of migraine during pregnancy and breastfeeding. Nat Rev Neurol. 2015 Apr;11(4):209-19. Review. Abstract
  4. Davanzo R, Bua J, Paloni G, Facchina G. Breastfeeding and migraine drugs. Eur J Clin Pharmacol. 2014 Abstract
  5. Pfizer. Eletriptan. Drug Summary. 2013 Full text (in our servers)
  6. AEMPS-Pfizer. Eletriptan (Relpax). Ficha técnica 2013 Full text (in our servers)
  7. Hutchinson S, Marmura MJ, Calhoun A, Lucas S, Silberstein S, Peterlin BL. Use of common migraine treatments in breast-feeding women: a summary of recommendations. Headache. 2013 Abstract Full text (link to original source) Full text (in our servers)
  8. Duong S, Bozzo P, Nordeng H, Einarson A. Safety of triptans for migraine headaches during pregnancy and breastfeeding. Can Fam Physician. 2010 Abstract Full text (link to original source) Full text (in our servers)
  9. Jürgens TP, Schaefer C, May A. Treatment of cluster headache in pregnancy and lactation. Cephalalgia. 2009 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM